Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Esophageal Neoplasms 1Cystitis, Interstitial 1

Interventions

pembrolizumab 16Radiotherapy 15Drug Therapy 14Paclitaxel 13Cisplatin 12Carboplatin 10Immunotherapy 9Esophagectomy 9Radiation 8Fluorouracil 8Surgical Procedures, Operative 7Capecitabine 7Blood Specimen Collection 7Oxaliplatin 6Nivolumab 6Immune Checkpoint Inhibitors 6Chemoradiotherapy 6nimotuzumab 5Trastuzumab 5130-nm albumin-bound paclitaxel 5sintilimab 4camrelizumab 4Leucovorin 4trastuzumab deruxtecan 3tislelizumab 3patritumab deruxtecan 3Surveys and Questionnaires 3Endoscopy 3Bevacizumab 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Esophageal Neoplasms × Hyaluronic Acid × Clear all
NCT06077981 2025-05-01

Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections

Instituto do Cancer do Estado de São Paulo

Phase NA Recruiting
30 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡